Whanin Pharmaceutical Company   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Korea, Republic of (1978)
Status: No NME R&D (1978)

Organization Overview

First Clinical Trial
2008
NCT01245530
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Whanin Pharmaceutical Company

Active Ingredients

Drugs in Phase 3 Trials (3)

angelica (1 trial)

cariprazine (vraylar) (1 trial)

donepezil (aricept) (1 trial)

Drugs in Phase 2 Trials (1)

win-901x (1 trial)

Drugs in Phase 1 Trials (3)

chlorpromazine (Thorazine) (1 trial)

clozapine (clozaril) (1 trial)

eslicarbazepine acetate (aptiom) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 3)

Asthma (Phase 2)

Dementia (Phase 3)

Seizures (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 7